본문으로 건너뛰기
← 뒤로

Radiolabeled Aptamers for Bioimaging Applications in Oncology and Infectious Diseases.

Journal of labelled compounds & radiopharmaceuticals 2025 Vol.68(14) p. e70001

Ullah N, Bruce-Tagoe TA, Asamoah GA, Soleimani S, Danquah MK

📝 환자 설명용 한 줄

Radiolabeled aptamers are promising molecular probes for bioimaging because of their potential for high specificity, stability, and rapid clearance from nontarget tissues.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ullah N, Bruce-Tagoe TA, et al. (2025). Radiolabeled Aptamers for Bioimaging Applications in Oncology and Infectious Diseases.. Journal of labelled compounds & radiopharmaceuticals, 68(14), e70001. https://doi.org/10.1002/jlcr.70001
MLA Ullah N, et al.. "Radiolabeled Aptamers for Bioimaging Applications in Oncology and Infectious Diseases.." Journal of labelled compounds & radiopharmaceuticals, vol. 68, no. 14, 2025, pp. e70001.
PMID 41371692
DOI 10.1002/jlcr.70001

Abstract

Radiolabeled aptamers are promising molecular probes for bioimaging because of their potential for high specificity, stability, and rapid clearance from nontarget tissues. They are single-stranded oligonucleotides labeled with radionuclides such as technetium-99m (ᵐTc), fluorine-18 (F), and gallium-68 (Ga) to enable precise imaging via single-photon emission computed tomography (SPECT) and positron emission tomography (PET). The versatility of radiolabeling strategies can provide opportunities to enhance biostability and pharmacokinetics while improving imaging sensitivity. In cancer theranostics, radiolabeled aptamers can allow early detection and treatment as well as facilitate effective monitoring of therapeutic responses. The applications of radiolabeled aptamers extend to infectious disease imaging, enabling real-time tracking of infections. Despite these advances, challenges such as rapid renal clearance, immunogenicity, and the need for clinical validation persist, catalyzing further research focused on enhancing the stability of radiolabeled aptamers, improving radiolabeling efficacy, and optimizing biodistribution. Emerging strategies, including nanoparticle conjugation and hybrid bioimaging, offer a great perspective for advancing the field. This article highlights recent advancements in radiolabeled aptamers in terms of their development, bioimaging applications, and research directions to address their limitations.

MeSH Terms

Humans; Aptamers, Nucleotide; Neoplasms; Radiopharmaceuticals; Animals; Communicable Diseases; Isotope Labeling

같은 제1저자의 인용 많은 논문 (2)